^
No biomarker
Urothelial Cancer
enfortumab vedotin
Sensitive: A1 - Approval
Seagen Press Release - 1 day
No biomarker
Prostate Cancer
olaparib
Sensitive: B - Late Trials
Merck (MSD) Press Release - 4 days
FGFR3 mutation
Urothelial Cancer
TAS 120
Sensitive: C2 – Inclusion Criteria
Cancer Discov - 6 days
FGFR1 mutation
Urothelial Cancer
TAS 120
Sensitive: C3 – Early Trials
Cancer Discov - 6 days
BRCA2 mutation
Prostate Cancer
olaparib
Sensitive: A1 - Approval
CAP 2021 - 1 week
PD-L1 expression
Urothelial Cancer
atezolizumab
Sensitive: A1 - Approval
ESMO 2021 - 2 weeks
VHL mutation
RCC
belzutifan
Sensitive: A1 - Approval
NCCN - 2 weeks
FGFR mutation
Urothelial Cancer
erdafitinib + JNJ-63723283
Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
AR-V7 positive
Prostate Cancer
cabazitaxel
Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
NANOGNB mutation
Clear Cell Renal Cell Carcinoma
Immunotherapy
Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
BRCA2 mutation
Prostate Cancer
avelumab
Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
ATM mutation
Prostate Cancer
avelumab
Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
CXCL13 elevation
Clear Cell Renal Cell Carcinoma
nivolumab
Resistant: C3 – Early Trials
ESMO 2021 - 2 weeks
TNFSF13B elevation
Clear Cell Renal Cell Carcinoma
nivolumab
Resistant: C3 – Early Trials
ESMO 2021 - 2 weeks
IL6 elevation
Clear Cell Renal Cell Carcinoma
nivolumab
Resistant: C3 – Early Trials
ESMO 2021 - 2 weeks
PTEN mutation
Prostate Cancer
enzalutamide + CC-115
Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
PTEN deletion
Prostate Cancer
enzalutamide + CC-115
Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
FGFR fusion
Urothelial Cancer
erdafitinib + JNJ-63723283
Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
FOLH1 expression
Prostate Cancer
pembrolizumab + 177 Lu PSMA-617
Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
CD276 overexpression
Prostate Cancer
DS-7300
Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
TMB-H
Prostate Cancer
pembrolizumab + enzalutamide
Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
EPHB2 expression
Urothelial Cancer
pembrolizumab + sEphB4-HSA
Sensitive: C3 – Early Trials
ESMO 2021 - 2 weeks
No biomarker
RCC
nivolumab + cabozantinib tablet
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
apalutamide
Sensitive: A1 - Approval
No biomarker
Urothelial Cancer
avelumab
Sensitive: A1 - Approval
No biomarker
Urothelial Cancer
sacituzumab govitecan-hziy
Sensitive: A1 - Approval
PD-L1 expression
RCC
avelumab + axitinib
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
histrelin acetate
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
cabazitaxel
Sensitive: A1 - Approval
BRCA1 mutation
Prostate Cancer
olaparib
Sensitive: A1 - Approval
No biomarker
RCC
avelumab + axitinib
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
enzalutamide
Sensitive: A1 - Approval
No biomarker
RCC
Mvasi (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
RCC
Zirabev (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
relugolix
Sensitive: A1 - Approval
No biomarker
RCC
sorafenib
Sensitive: A1 - Approval
No biomarker
RCC
tivozanib
Sensitive: A1 - Approval
No biomarker
Urothelial Cancer
mitomycin urothelial gel
Sensitive: A1 - Approval
No biomarker
RCC
temsirolimus
Sensitive: A1 - Approval
No biomarker
RCC
sunitinib
Sensitive: A1 - Approval
No biomarker
RCC
everolimus + lenvatinib
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
docetaxel + prednisone
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
abiraterone acetate
Sensitive: A1 - Approval
No biomarker
RCC
everolimus
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
degarelix
Sensitive: A1 - Approval
PD-L1 expression
Urothelial Cancer
pembrolizumab
Sensitive: A1 - Approval
No biomarker
RCC
bevacizumab + pegylated interferon α -2a
Sensitive: A1 - Approval
ATM mutation
Prostate Cancer
olaparib
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
darolutamide
Sensitive: A1 - Approval
No biomarker
RCC
cabozantinib tablet
Sensitive: A1 - Approval
No biomarker
Bladder Cancer
cisplatin
Sensitive: A1 - Approval
No biomarker
RCC
pembrolizumab + lenvatinib
Sensitive: A1 - Approval
No biomarker
RCC
pembrolizumab + axitinib
Sensitive: A1 - Approval
No biomarker
RCC
nivolumab
Sensitive: A1 - Approval
FGFR2 mutation
Urothelial Cancer
erdafitinib
Sensitive: A1 - Approval
No biomarker
RCC
Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a
Sensitive: A1 - Approval
No biomarker
RCC
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Urothelial Cancer
nivolumab
Sensitive: A1 - Approval
No biomarker
RCC
nivolumab + ipilimumab
Sensitive: A1 - Approval
No biomarker
Urothelial Cancer
pembrolizumab
Sensitive: A1 - Approval
FGFR3 mutation
Urothelial Cancer
erdafitinib
Sensitive: A1 - Approval
No biomarker
RCC
axitinib
Sensitive: A1 - Approval
No biomarker
RCC
pazopanib
Sensitive: A1 - Approval
BRCA1 mutation
Prostate Cancer
rucaparib
Sensitive: A1 - Approval
BRCA2 mutation
Prostate Cancer
rucaparib
Sensitive: A1 - Approval
No biomarker
RCC
aldesleukin
Sensitive: A1 - Approval
No biomarker
Urothelial Cancer
atezolizumab
Sensitive: A1 - Approval
HRD
Prostate Cancer
olaparib
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
zoledronic acid
Sensitive: A1 - Approval
PD-L1 overexpression
Urothelial Cancer
tislelizumab
Sensitive: A1 - Approval
No biomarker
RCC
Bevax (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Urothelial Cancer
toripalimab
Sensitive: A1 - Approval
No biomarker
RCC
Krabeva (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
leuprolide mesylate injectable suspension
Sensitive: A1 - Approval
No biomarker
Bladder Cancer
EP
Sensitive: A2 - Guideline
MSI-H/dMMR
Prostate Cancer
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Prostate Cancer
mitoxantrone
Sensitive: A2 - Guideline
No biomarker
Prostate Cancer
etoposide IV
Sensitive: A2 - Guideline
No biomarker
Prostate Cancer
atezolizumab
Sensitive: A2 - Guideline
No biomarker
RCC
bevacizumab
Sensitive: A2 - Guideline
No biomarker
Clear Cell Renal Cell Carcinoma
bevacizumab + pegylated interferon α -2a
Sensitive: A2 - Guideline
PD-L1 expression
Bladder Cancer
atezolizumab
Sensitive: A2 - Guideline
PD-L1 expression
Bladder Cancer
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Clear Cell Renal Cell Carcinoma
avelumab + axitinib
Sensitive: A2 - Guideline
No biomarker
Clear Cell Renal Cell Carcinoma
pembrolizumab + axitinib
Sensitive: A2 - Guideline
No biomarker
RCC
bevacizumab + erlotinib
Sensitive: A2 - Guideline
No biomarker
RCC
erlotinib
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
capecitabine
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
carboplatin + etoposide IV
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
cisplatin + doxorubicin hydrochloride + ifosfamide + etoposide IV
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
cisplatin + paclitaxel
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
cisplatin + 5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
enfortumab vedotin
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
docetaxel
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
paclitaxel
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
gemcitabine + ifosfamide + pegylated liposomal doxorubicin
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
paclitaxel + gemcitabine
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
gemcitabine
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
carboplatin + gemcitabine
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
cisplatin + gemcitabine
Sensitive: A2 - Guideline
No biomarker
Prostate Cancer
docetaxel
Sensitive: A2 - Guideline
CDK12 mutation
Prostate Cancer
olaparib
Sensitive: A2 - Guideline
PALB2 mutation
Prostate Cancer
olaparib
Sensitive: A2 - Guideline
No biomarker
Urothelial Cancer
durvalumab
Sensitive: A2 - Guideline
No biomarker
Clear Cell Renal Cell Carcinoma
sunitinib
Sensitive: A2 - Guideline
No biomarker
Clear Cell Renal Cell Carcinoma
pazopanib
Sensitive: A2 - Guideline
No biomarker
Clear Cell Renal Cell Carcinoma
temsirolimus
Sensitive: A2 - Guideline
CHEK2 mutation
Prostate Cancer
olaparib
Sensitive: A2 - Guideline
CHEK1 mutation
Prostate Cancer
olaparib
Sensitive: A2 - Guideline
AR splice variant 7
Prostate Cancer
abiraterone acetate
Resistant: A2 - Guideline
AR splice variant 7
Prostate Cancer
enzalutamide
Resistant: A2 - Guideline
RAD51B mutation
Prostate Cancer
olaparib
Sensitive: A2 - Guideline